Get Premium to unlock powerful stock data
NAS:ACXP (USA)  
Acurx Pharmaceuticals Inc logo

Acurx Pharmaceuticals Inc

$ 3.75 -0.04 (-1.06%) 08:08 PM EST
P/E:
At Loss
P/B:
3.60
Market Cap:
$ 38.49M
Enterprise V:
$ 35.92M
Volume:
10.51K
Avg Vol (2M):
18.67K
Also Trade In:
Volume:
10.51K
Market Cap $:
38.49M
PE Ratio:
At Loss
Avg Vol (2-Month):
18.67K
Enterprise Value $:
35.92M
PB Ratio:
3.60
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Acurx Pharmaceuticals Inc
NAICS : 325412 SIC : 2834
259 Liberty Avenue, Staten Island, NY, USA, 10305
Description
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.94
Interest Coverage No Debt
Piotroski F-Score N/A/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 59.19
9-Day RSI 62.73
14-Day RSI 61.44
6-1 Month Momentum % -41.92
12-1 Month Momentum % -59.39

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 17.89
Quick Ratio 17.89
Cash Ratio 17.51

Dividend & Buy Back

Name Current Vs Industry Vs History
Name Current Vs Industry Vs History
ROE % -125.91
ROA % -116.21
ROIC % -5916.39
ROCE % -126.4

Financials (Next Earnings Date:2022-08-17 Est.)

ACXP's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:ACXP

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -1.51
Beta 0
Volatility % 58.33
14-Day RSI 61.44
14-Day ATR ($) 0.246432
20-Day SMA ($) 3.472745
12-1 Month Momentum % -59.39
52-Week Range ($) 2.33 - 6.35
Shares Outstanding (Mil) 10.26

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Acurx Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More